Low Thermal Plasma for Marginal Ulcers
(AMULET Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment for marginal ulcers, painful sores that can develop after weight loss surgeries like gastric bypass. The study compares a new method using Low Thermal Plasma (LTP) treatment to the usual treatment with medications called PPIs. People who have had a gastric bypass and experience symptoms like stomach pain, nausea, or difficulty swallowing might be suitable candidates. The researchers aim to demonstrate that LTP is less invasive and more effective than surgery for healing these ulcers. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance future treatment options.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must be willing to follow the standard treatment, which includes taking PPIs (medications that reduce stomach acid). If you are currently using systemic antibiotics, you cannot participate in the trial.
What prior data suggests that Low Thermal Plasma treatment is safe for marginal ulcers?
Research has shown that Low Thermal Plasma (LTP) treatment has been safely used in various medical fields. Studies have found it effective for controlling bleeding in ulcers and removing cancerous tissues, indicating that LTP is generally well-tolerated in these cases. While some studies have not found significant clinical benefits in wound treatment, other research highlights LTP's success in speeding up wound healing and reducing wound size. Overall, LTP is generally considered safe, with some potential benefits for healing.12345
Why are researchers excited about this trial?
Researchers are excited about Low Thermal Plasma (LTP) treatment for marginal ulcers because it offers a new way to enhance healing by using plasma energy to target the ulcer directly. While standard care for marginal ulcers typically involves proton pump inhibitors (PPIs) to reduce stomach acid, LTP aims to promote tissue regeneration at the site of the ulcer itself. This innovative approach could potentially accelerate healing and improve outcomes for patients, setting it apart from conventional treatments that primarily focus on symptom management.
What evidence suggests that Low Thermal Plasma is effective for treating marginal ulcers?
Research has shown that Low Thermal Plasma (LTP), which participants in this trial may receive, effectively heals various ulcers and wounds, including pressure sores and recurring mouth ulcers. One study found that LTP helped wounds heal by reducing their size and speeding up recovery. Another study demonstrated that cold atmospheric plasma, similar to LTP, also accelerated wound healing. LTP has been used safely and effectively to manage bleeding ulcers and remove cancerous tissue. These findings suggest that LTP could help treat marginal ulcers by promoting quicker healing.12467
Who Is on the Research Team?
Christopher Thompson, MD
Principal Investigator
Brigham and Womens Hospital
Are You a Good Fit for This Trial?
This trial is for individuals with marginal ulcers, which can cause symptoms like gastrointestinal bleeding, vomiting, abdominal pain, and difficulty swallowing. Participants should have a history of Roux-en-Y anastomosis surgery that led to these ulcers.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Low Thermal Plasma (LTP) treatment of the ulcer in addition to standard of care (PPI administration) or only the standard of care treatment (PPI administration).
Follow-up
Participants are monitored for safety and effectiveness after treatment, including ulcer healing success rate and improvement of tissue oxygenation.
What Are the Treatments Tested in This Trial?
Interventions
- Low Thermal Plasma (LTP) Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Christopher C. Thompson, MD, MSc
Lead Sponsor
Erbe USA Incorporated
Collaborator